Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7 th2010"
1 Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
2 Office of the Director, Office of Science Policy Analysis, Office of Science Policy, National Institutes of Health, Bethesda, MD, USA
3 Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council (CNR), Sassari, Italy
4 Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA
5 Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
6 Center for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, CA, USA
7 University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
8 Infectious Diseases and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and Center for Human Immunology (CHI), NIH, Bethesda, Maryland, USA
9 David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
10 Unit of Immunotherapy of Human Tumors, IRCCS Foundation, Istituto Nazionale Tumori, Milan, Italy
11 Department of Medicine, Stanford University, Stanford, CA, USA
12 Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA
13 Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon, USA
14 Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, and Melanoma Program, Pittsburgh Cancer Institute, Pittsburgh, PA, USA
15 Clinical Investigations Branch, Cancer Therapy Evaluation Program DCTD, National Cancer Institute, Bethesda, MD, USA
16 Cancer Immunotherapeutics Business Unit, GlaxoSmithKline Biologicals, Rixensart, Belgium
17 Yale Cancer Center, New Haven, CT, USA
18 Indiana University Health Goshen Center for Cancer Care, Goshen, IN, USA
19 Medical Oncology and Immunotherapy, Department of Oncology, University, Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
20 Massachusetts General Hospital Cancer Center, Boston, MA, USA
21 Inserm Group Leader, Inserm U872, Team 15, Cordeliers Research Center, Paris, France
22 Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA
23 Surgical Brach, NIH, Bethesda, MA, USA
Journal of Translational Medicine 2011, 9:32 doi:10.1186/1479-5876-9-32Published: 26 March 2011
Progress in understanding the molecular basis of melanoma has made possible the identification of molecular targets with important implications in clinical practice. In fact, new therapeutic approaches are emerging from basic science and it will be important to implement their rapid translation into clinical practice by active clinical investigation.
The first meeting of Melanoma Research: a bridge Naples-USA, organized by Paolo A. Ascierto (INT, Naples, Italy) and Francesco Marincola (NIH, Bethesda, USA) took place in Naples, on 6-7 December 2010.
This international congress gathered more than 30 international and Italian faculty members and was focused on recent advances in melanoma molecular biology, immunology and therapy, and created an interactive discussion across Institutions belonging to Government, Academy and Pharmaceutical Industry, in order to stimulate new approaches in basic, translational and clinical research. Four topics of discussion were identified: New pathways in Melanoma, Biomarkers, Clinical Trials and New Molecules and Strategies.